Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Antengene Corporation Limited ( (HK:6996) ) just unveiled an announcement.
Antengene Corporation Limited announced that the Indonesia National Agency of Drug and Food Control has approved the New Drug Application for XPOVIO® (selinexor) for three specific indications, including treatments for multiple myeloma and diffuse large B-cell lymphoma. This approval marks a significant milestone for Antengene, enhancing its market presence in the Asia Pacific region and potentially improving treatment options for patients with these conditions.
More about Antengene Corporation Limited
Antengene Corporation Limited is a leading commercial-stage, research and development-driven global biopharmaceutical company. It focuses on discovering, developing, manufacturing, and commercializing innovative first-in-class and best-in-class therapeutics for treating hematologic malignancies and solid tumors. Since its inception in 2017, Antengene has built a diverse pipeline of oncology assets, with multiple investigational new drug approvals and new drug applications across the Asia Pacific region.
YTD Price Performance: 370.0%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €194.9M
See more data about 6996 stock on TipRanks’ Stock Analysis page.